ERBB2 and breast cancer: Immunohistochemistry (IHC) analyses highlighted that the highest proportion of ALDH1-expressing epithelial CSCs is observed in the HER2+ BC subtype, and consistently, ALDH1 expression was found to be associated with a poor prognosis in a cohort of 203 primary BC patients [54].